Plant Name: Cephalaria grossheimii
Taxonomic Information:
Plant ID: NPO13076
Plant Latin Name: Cephalaria grossheimii
Taxonomy Genus: Cephalaria
Taxonomy Family: Caprifoliaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPR35; | |
| NPSR1; | |
| RECQL; TDP1; TERT; GLO1; PGD; ALOX12; HPGD; AKR1B1; HSD17B2; HSD17B10; NOX4; APEX1; POLB; | |
| ACHE; | |
| BCL2; | |
| TOP2A; | |
| TEK; INSR; AXL; MET; FLT3; CDK1; EGFR; PIM1; NUAK1; SRC; KDR; IGF1R; AURKB; CSNK2A1; | |
| CA2; CA12; CA7; CA4; | |
| TYR; | |
| KDM4E; | |
| F10; F2; | |
| AHR; | |
| FUT7; | |
| DNMT1; | |
| SLC22A6; | |
| ABCB1; | |
| LMNA; SMAD3; HSPA1A; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| DNA methyltransferase | DNMT1 | DNA (cytosine-5)-methyltransferase 1 | P26358 | CHEMBL1993 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Serine protease | F10 | Coagulation factor X | P00742 | CHEMBL244 |
| Serine protease | F2 | Thrombin | P00734 | CHEMBL204 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 6.858E-09 | 2.588E-06 | AXL, EGFR, F10, INSR, MET, NOX4, SRC, TEK |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 2.493E-08 | 7.869E-06 | ABCB1, AURKB, AXL, CDK1, CSNK2A1, EGFR, FLT3, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, PIM1, RECQL, SRC, TEK, TOP2A |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.235E-08 | 1.676E-05 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.635E-07 | 3.632E-05 | EGFR, IGF1R, INSR, KDR, SRC |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 4.911E-07 | 9.141E-05 | ACHE, BCL2, CDK1, CYP1A1, EGFR, F2, SMAD3 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 5.108E-07 | 9.426E-05 | AKR1B1, ALOX12, APEX1, CYP1A1, CYP1A2, CYP1B1, HPGD, HSD17B10, HSD17B2, KDM4E, NOX4, PGD, TYR |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 6.162E-07 | 1.082E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.346E-06 | 2.109E-04 | BCL2, CA2, CA7, F2, KDR, NPSR1, SRC |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.528E-06 | 2.360E-04 | EGFR, INSR, KDR |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.856E-06 | 2.750E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 2.179E-06 | 3.163E-04 | ABCB1, CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.179E-06 | 3.163E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0040011; locomotion | GO:0014911; positive regulation of smooth muscle cell migration | 2.581E-06 | 3.649E-04 | BCL2, NOX4, SRC, TERT |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.581E-06 | 3.649E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.853E-06 | 7.916E-04 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.412E-06 | 8.453E-04 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 7.108E-06 | 9.159E-04 | APEX1, POLB |
| MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 9.466E-06 | 1.151E-03 | ACHE, APEX1, CSNK2A1, EGFR, FLT3, IGF1R, INSR, KDR, L3MBTL1, PIM1, SMAD3, SRC |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.036E-05 | 1.240E-03 | CA2, CA4, EGFR, HPGD, SLC22A6, TEK |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 1.048E-05 | 1.247E-03 | AHR, AXL, BCL2, CSNK2A1, EGFR, SRC, TOP2A |
| BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 1.439E-05 | 1.640E-03 | CDK1, EGFR, IGF1R, INSR |
| BP | GO:0050896; response to stimulus | GO:0046686; response to cadmium ion | 1.546E-05 | 1.736E-03 | CDK1, CYP1A2, EGFR, TERT |
| MF | GO:0003824; catalytic activity | GO:0016616; oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 1.682E-05 | 1.859E-03 | AKR1B1, HPGD, HSD17B10, HSD17B2, PGD |
| BP | GO:0008152; metabolic process | GO:0070988; demethylation | 1.905E-05 | 2.043E-03 | APEX1, CYP1A1, CYP1A2, KDM4E |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.129E-05 | 2.250E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.365E-05 | 2.464E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.392E-05 | 2.481E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4, SRC |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 2.578E-05 | 2.644E-03 | EGFR, IGF1R, INSR, KDR, TEK |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 2.975E-05 | 2.985E-03 | F2, FLT3, KDR, TEK |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 3.137E-05 | 3.092E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.137E-05 | 3.092E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.250E-05 | 3.872E-03 | CYP1A1, CYP1A2 |
| BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 4.893E-05 | 4.314E-03 | EGFR, INSR, KDR, NOX4, SMAD3, SRC |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 5.090E-05 | 4.470E-03 | ACHE, AKR1B1, APEX1, CA4, EGFR, HSPA1A, NOX4, SRC, TYR |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 5.191E-05 | 4.504E-03 | AKR1B1, EGFR, HPGD, TERT |
| BP | GO:0009987; cellular process | GO:0046427; positive regulation of JAK-STAT cascade | 5.465E-05 | 4.703E-03 | AKR1B1, CYP1B1, F2, FLT3 |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 5.563E-05 | 4.769E-03 | AHR, AKR1B1, APEX1, AURKB, BCL2, CDK1, CSNK2A1, DNMT1, HPGD, HSPA1A, L3MBTL1, LMNA, NUAK1, PIM1, POLB, RECQL, SMAD3, SRC, TERT, TOP2A |
| BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 5.799E-05 | 4.952E-03 | ALOX12, CYP1B1, KDR, TEK, TERT |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 6.399E-05 | 5.319E-03 | AXL, IGF1R, INSR |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 7.097E-05 | 5.702E-03 | FLT3, SRC, TEK |
| BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 7.401E-05 | 5.903E-03 | CDK1, EGFR, FLT3, INSR, NOX4, SRC |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 8.048E-05 | 6.236E-03 | ACHE, EGFR, IGF1R, INSR |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 8.637E-05 | 6.646E-03 | AHR, CSNK2A1, KDR |
| BP | GO:0009987; cellular process | GO:2001240; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 1.038E-04 | 7.637E-03 | BCL2, HSPA1A, TERT |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 1.059E-04 | 7.695E-03 | ALOX12, HPGD |
| BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 1.064E-04 | 7.695E-03 | BCL2, CA2, EGFR, MET, SMAD3, SRC |
| BP | GO:0009987; cellular process | GO:1900087; positive regulation of G1/S transition of mitotic cell cycle | 1.234E-04 | 8.781E-03 | APEX1, CYP1A1, TERT |
| BP | Unclassified; | GO:0006461; protein complex assembly | 1.283E-04 | 8.980E-03 | ACHE, CDK1, HSD17B10, HSPA1A, IGF1R, INSR, SLC22A6, SMAD3, SRC, TEK, TERT |
| BP | GO:0050896; response to stimulus | GO:0051591; response to cAMP | 1.292E-04 | 9.016E-03 | APEX1, NOX4, TEK, TYR |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 1.311E-04 | 9.121E-03 | EGFR, INSR, KDR, SLC22A6, SRC, TEK |
| BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 1.399E-04 | 9.591E-03 | CDK1, EGFR, F2, SMAD3 |
| BP | GO:0009987; cellular process | GO:0045930; negative regulation of mitotic cell cycle | 1.464E-04 | 9.825E-03 | AURKB, BCL2, CDK1, EGFR, SMAD3, TOP2A |
| BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 1.480E-04 | 9.825E-03 | EGFR, POLB |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 1.480E-04 | 9.825E-03 | FLT3, KDR |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 8.315E-10 | 1.156E-07 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.892E-07 | 8.764E-06 | INSR, HSD17B2, CYP1A1, CYP1B1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.178E-06 | 4.093E-05 | SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 9.429E-08 | 6.553E-06 | CA12, CA2, CA4, CA7 |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 4.583E-06 | 1.274E-04 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 7.045E-06 | 1.632E-04 | INSR, BCL2, TEK, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.120E-05 | 2.224E-04 | DNMT1, ABCB1, PIM1, BCL2, CYP1B1, MET, EGFR |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.363E-05 | 2.368E-04 | SRC, KDR, BCL2, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 2.726E-05 | 3.445E-04 | INSR, KDR, BCL2, TEK, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 2.634E-05 | 3.445E-04 | INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.554E-05 | 2.400E-04 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.809E-04 | 1.934E-03 | SRC, KDR, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.546E-04 | 5.139E-03 | SMAD3, FLT3, BCL2, MET, EGFR, IGF1R |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.530E-04 | 1.773E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 3.952E-04 | 3.923E-03 | SMAD3, INSR, EGFR, IGF1R |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 6.175E-04 | 5.365E-03 | INSR, HSPA1A, IGF1R |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.167E-03 | 7.676E-03 | DNMT1, FUT7, HSD17B2, CYP1A2, CYP1A1, AKR1B1, ALOX12, PGD, TYR, HSD17B10 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 7.062E-04 | 5.694E-03 | FLT3, MET, EGFR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 7.374E-04 | 5.694E-03 | SRC, MET, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 8.364E-04 | 6.119E-03 | MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.226E-03 | 7.676E-03 | HPGD, FLT3, MET, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.068E-04 | 6.302E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 1.872E-03 | 9.638E-03 | CSNK2A1, BCL2, CDK1, HSPA1A |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.608E-03 | 8.660E-03 | BCL2, EGFR, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.557E-03 | 8.660E-03 | SRC, CDK1, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.270E-03 | 7.676E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.620E-03 | 8.660E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Heart arrhythmia | I47-I49 | F2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; |
| I00-I99: Diseases of the circulatory system | Deep venous clots | I80.2 | F10; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TERT; KDR; EGFR; AKR1B1; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| NA: NA | Haemophilia B | NA | F10; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; TYR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; |
| NA: NA | Nonvalvular atrial fibrillation | NA | F2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; DNMT1; EGFR; ABCB1; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F10; F2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | F2; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; EGFR; SRC; |
| C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | DNMT1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; KDR; FLT3; TEK; EGFR; SRC; ABCB1; F2; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; TERT; KDR; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| C00-D49: Neoplasms | Melanoma | C43 | TERT; KDR; EGFR; TYR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| I00-I99: Diseases of the circulatory system | Prophylaxis of deep vein thrombosis | I80-I82, I80.2 | F10; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F10; F2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; TERT; FLT3; DNMT1; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; DNMT1; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SRC; |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | F10; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; F2; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; FLT3; ACHE; TEK; DNMT1; EGFR; SRC; ABCB1; F2; BCL2; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; F10; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood forming organ disorders | D75.9 | F2; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; TERT; KDR; FLT3; INSR; EGFR; BCL2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; BCL2; |
| C00-D49: Neoplasms | Prostate cancer | C61 | TERT; FLT3; EGFR; BCL2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | DNMT1; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; BCL2; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; TERT; AHR; SRC; BCL2; |
| NA: NA | Edema | NA | CA2; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F10; F2; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F10; F2; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F10; F2; |
| I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F10; F2; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; INSR; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | DNMT1; EGFR; SRC; |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; BCL2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | F10; EGFR; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| NA: NA | Christmas disease | NA | F10; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; BCL2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
| I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F10; F2; |
| NA: NA | HIV infections | NA | AHR; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Stroke in atrial fibrillation | I48, I61-I63 | F2; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; EGFR; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hematology | D50-D77 | F10; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hemophilia | D66-D68 | F10; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Thrombocytopenia | D69.6, P61.0 | F2; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F10; F2; |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F10; F2; |
| I00-I99: Diseases of the circulatory system | Thromboembolic disorders | I80-I82 | F10; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | F10; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; INSR; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT; KDR; FLT3; EGFR; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; F2; |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | F2; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | F2; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; KDR; EGFR; ABCB1; |
| I00-I99: Diseases of the circulatory system | Deep vein thrombosis | I80-I82, I80.2 | F10; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
